Asthma Therapeutics Market Size & Share 2024 - 2032

Asthma Therapeutics Market Size

Asthma Therapeutics Market size was valued at around USD 25.7 billion in 2023 and is estimated to grow at a CAGR of 4.4% between 2024 and 2032. This robust market growth can be attributed to factors such as the growing prevalence of asthma, rising expenditure on the R&D of novel biologics, and an increase in awareness regarding asthma management.

The growing prevalence of asthma places an increased burden on healthcare systems globally. According to the World Health Organization, asthma affected an estimated 262 million people in 2019 and caused 455,000 deaths around the globe. As a chronic condition that often requires long-term management, asthma necessitates ongoing medical attention, regular monitoring, and access to a diverse range of therapeutic options. This burden on healthcare systems underscores the imperative for continuous advancements and investment in asthma therapeutics.
 

Moreover, a crucial aspect fueling the growth of asthma therapeutics is the heightened awareness about asthma and improved diagnostic capabilities. The emphasis on early detection and intervention has led to more accurate diagnoses, enabling timely initiation of treatment. This increased awareness among healthcare professionals and the general population is fostering a proactive approach to asthma management.
 

Asthma therapeutics refer to the diverse range of medical interventions and treatments designed to manage and alleviate the symptoms of asthma, a chronic respiratory condition characterized by inflammation and constriction of the airways. Asthma therapeutics aim to address the underlying inflammation, bronchoconstriction, and airway hyperresponsiveness associated with asthma, providing patients with tailored and comprehensive strategies for the management of their condition.
 

Asthma Therapeutics Market Trends

The asthma therapeutics industry is undergoing a transformative phase fuelled by technological advancements that are reshaping the landscape of asthma management, offering innovative solutions that enhance diagnostics, treatment efficacy, and patient outcomes.
 

• Technological advancements have given rise to smart inhalers and digital inhalation devices, transforming the way individuals administer and monitor their asthma medications. These therapeutic respiratory devices are equipped with sensors and connectivity features that track medication usage, provide real-time feedback, and enable healthcare professionals to remotely monitor patient adherence. Smart inhalers enhance treatment adherence and contribute to more effective asthma management.
   
• Moreover, the integration of telemedicine and remote monitoring technologies is revolutionizing asthma care by offering virtual consultations and continuous patient monitoring. Patients can communicate with healthcare providers, receive personalized treatment plans, and have their asthma symptoms remotely assessed. Telemedicine enhances accessibility to healthcare services, particularly for individuals with asthma in remote or underserved areas.
   
• Furthermore, advancements in genomics and biomarker discovery are driving the shift towards personalized medicine in asthma therapeutics. By analyzing genetic profiles and identifying specific biomarkers associated with asthma subtypes, researchers can tailor treatment strategies to individual patients. This precision medicine approach aims to optimize therapeutic outcomes by addressing the unique genetic and molecular characteristics of each patient.
   

Asthma Therapeutics Market Analysis

Based on drug class, the asthma therapeutics market is categorized into combination therapies (ICS/LABAs), long-acting beta agonists (LABAs), short-acting beta agonists (SABAs), inhaled corticosteroids (ICS), oral and intravenous corticosteroids, leukotriene modifiers, and other drug classes. The combination therapies (ICS/LABAs) segment accounted for the majority share and was valued at over USD 6.6 billion in revenue in 2023.
 

• Combination therapies featuring ICS and LABAs leverage the synergistic effects of these two classes of medications. Inhaled corticosteroids mitigate airway inflammation, while long-acting beta-agonists promote bronchodilation. The combined action addresses both components of asthma pathophysiology, providing comprehensive relief to patients and contributing to the effectiveness of the treatment.
   
• Additionally, the versatility of combination therapies allows for personalized treatment strategies. Healthcare professionals can tailor the dosage and combination ratio based on the severity and specific characteristics of an individual's asthma. This flexibility ensures that patients receive a treatment plan optimized for their unique needs, fostering a more personalized and effective approach to asthma management.
   

Based on treatment type, the asthma therapeutics market is categorized into long-term asthma control medications and quick-relief (rescue) medications. The long-term asthma control medications accounted for the majority share and were valued at over USD 14.8 billion in revenue in 2023.
 

• Long-term asthma control medications are designed to provide ongoing management of symptoms, ensuring sustained relief for individuals with asthma. By addressing underlying inflammation and bronchoconstriction, these medications contribute to the consistent control of asthma, minimizing the impact of day-to-day challenges associated with the condition.
   
• A key attribute of long-term control medications is their effectiveness in preventing asthma exacerbations. By maintaining airway stability and reducing the risk of acute episodes, these medications significantly contribute to the overall well-being of asthma patients. This preventive aspect enhances patient quality of life and reduces the burden on healthcare systems.
   
• Moreover, inhaled corticosteroids, a common component of long-term control medications, play a central role in reducing airway inflammation. This anti-inflammatory action not only addresses the root cause of asthma but also fosters a sustained improvement in lung function. The consistent use of long-term control medications contributes to the long-term suppression of inflammation. Therefore, the ongoing evolution of long-term asthma control medications has led to increased adoption of asthma therapeutics resulting in market expansion.
   

Based on the route of administration, the asthma therapeutics market is segmented into inhaled, oral, and injectable. The inhaled segment is anticipated to reach USD 20 billion by 2032.
 

• Inhaled medications enable targeted delivery directly to the airways, allowing for rapid and effective action at the site of inflammation and bronchoconstriction. This targeted approach enhances the therapeutic efficacy of medications, providing swift relief from symptoms and optimizing the management of acute and chronic aspects of asthma.
   
• The inhaled route of administration minimizes systemic side effects, a crucial advantage in asthma treatment. By delivering medications directly to the lungs, the risk of widespread systemic absorption and associated side effects is reduced. This characteristic not only enhances the safety profile of inhaled therapies but also improves patient tolerance and adherence.
   
• The user-friendly nature of inhaled therapies makes them highly accessible and convenient for patients. Inhalers, nebulizers, and dry powder devices provide easy and efficient administration, empowering patients to self-manage their condition. This patient-friendly approach enhances medication adherence and fosters a sense of control over asthma symptoms, contributing to the overall market progress.
   

Based on distribution channel, the asthma therapeutics market is segmented into brick & mortar, hospital pharmacies, and e-commerce. The brick & mortar segment held the leading revenue share in 2023 and is anticipated to reach USD 16.4 billion by 2032.
 

• The dominance of brick-and-mortar entities is amplified by their role in patient education and counselling. Pharmacists and healthcare professionals at these establishments provide valuable information to asthma patients regarding proper medication usage, adherence, potential side effects, and lifestyle management. This educational component contributes significantly to the overall effectiveness of asthma therapeutics.
   
• Moreover, for individuals experiencing acute asthma symptoms or exacerbations, brick-and-mortar pharmacies offer immediate access to rescue medications. The availability of short-acting beta-agonists and other rescue inhalers ensures that patients can promptly address sudden onset symptoms, contributing to the prompt management of asthma exacerbations.
   
• Furthermore, pharmacies within brick-and-mortar establishments provide a diverse array of asthma therapeutics, ranging from prescription medications to over-the-counter options. This diversity accommodates the varied needs of individuals with asthma, offering tailored solutions and contributing to the market growth of asthma therapeutics.
  
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end-use, the asthma therapeutics market is segmented into hospitals & clinics, ambulatory surgical centers, and homecare settings. The homecare settings segment accounted for USD 13.4 billion in revenue in 2023.
 

• The dominant market share held by homecare settings is reinforced by the convenience and accessibility it offers. Patients can administer asthma therapeutics from the comfort of their homes, eliminating the need for frequent visits to healthcare facilities. This convenience not only enhances the overall patient experience but also ensures consistent and timely administration of medications.
   
• The widespread adoption of inhaler devices and smart technologies has been instrumental in promoting self-administration. Inhalers, whether metered-dose inhalers (MDIs) or dry powder inhalers (DPIs), provide a user-friendly and portable means for individuals to self-administer asthma medications. Integration with smart technologies enhances medication adherence through features such as reminders, tracking, and data connectivity.
  
   

North America asthma therapeutics market accounted for USD 10.2 billion in revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline. The region's prominence is marked by a convergence of factors, including robust healthcare infrastructure, extensive research and development initiatives, and a high prevalence of ocular inflammatory conditions.
 

• The dominance of North America in asthma therapeutics is propelled by its leadership in research and development initiatives. Academic institutions, pharmaceutical companies, and research centers across the region actively contribute to the discovery of novel treatment modalities, innovative drugs, and advanced technologies, shaping the trajectory of asthma therapeutics globally.
   
• Moreover, North America witnesses a high prevalence of asthma cases, with diverse demographic and environmental factors contributing to the burden of respiratory conditions. For instance, according to the Asthma and Allergy Foundation of America, in 2023, more than 27 million people in the U.S. had asthma. This elevated incidence amplifies the market demand for asthma therapeutics, as healthcare providers work diligently to address the diverse needs of individuals grappling with asthma in the region.
   

Asthma Therapeutics Market Share

The asthma therapeutics industry is fragmented in nature, with various large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products with improved efficiency and cost-effectiveness are among a key market strategy for asthma therapeutics product manufacturers. Some of the leading industry players including AstraZeneca, Boehringer Ingelheim GSK plc, and Merck & Co., Inc., among others have a substantial presence in the market.
 

Asthma Therapeutics Market Companies

Some of the eminent market participants operating in the asthma therapeutics industry include:

• AstraZeneca
• Boehringer Ingelheim
• Cipla Ltd.
• Covis Pharma
• GSK plc
• Merck & Co., Inc.
• Novartis Pharmaceuticals Corporation
• Regeneron Pharmaceuticals, Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.
   

Asthma Therapeutics Industry News:

• In January 2024, GSK plc and Aiolos Bio, Inc. announced that they have entered into an agreement under which GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focused on addressing the needs of patients with certain respiratory and inflammatory conditions. AIO-001 has the potential to expand GSK’s respiratory biologics portfolio to reach a broader portion of asthma patients.
   
• In July 2020, Novartis announced that the European Commission (EC) has approved Enerzair Breezhaler as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2agonist (LABA) and a high dose of an inhaled corticosteroid (ICS). This approval helped the company solidify its asthma therapeutics product portfolio.
   

The asthma therapeutics market research report includes an in-depth coverage of the industry with estimates & forecasts in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Combination therapies (ICS/LABAs)
• Long-acting beta agonists (LABAs)
• Short-acting beta agonists (SABAs)
• Inhaled corticosteroids (ICS)
• Oral and intravenous corticosteroids
• Leukotriene modifiers
• Other drug classes

Market, By Treatment Type

• Long-term asthma control medications
• Quick-relief (rescue) medications

Market, By Route of Administration

• Topical
• Oral
• Injectables

Market, By Distribution Channel

• Brick & mortar
• Hospital pharmacies
• E-commerce

Market, By End-use

• Hospitals & clinics
• Ambulatory surgical centers
• Homecare settings

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa